Author

C. S. Hackett

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Dupuy· 1 shared A. G. Rust· 1 shared A. Grossman· 1 shared A. Liu· 1 shared A. Vaishnavi· 1 shared C. A. Klebanoff· 1 shared C. Stehn· 1 shared D. Adams· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Dupuy

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit

F. Yi, T. Cohen, N. Zimmerman, F. A. Dundar, P. Zumbo, R. Eltilib, E. J. Brophy, H. Arkin, J. Feucht, M. V. Gormally, C. S. Hackett, K. N. Kropp, I. Etxeberria, S. S. Chandran, J. H. Park, , C. A. Klebanoff

This study identifies FASLG expression patterns and shows that FAS-L/FAS auto-regulation governs CAR-T and CAR-NK cell persistence, enhancing antitumor efficacy when FAS is inhibited.

bioRxiv · Feb 26, 2024 · PreprintImmunology

"Transposon Mutagenesis Reveals RBMS3 as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis."

A. Vaishnavi, J. Juan, M. T. Scherzer, J. E. VanVeen, C. Stehn, C. S. Hackett, A. Dupuy, S. A. Chmura, L. van der Weyden, J. Y. Newberg, K. M. Mann, A. Liu, A. G. Rust, W. A. Weiss, D. Adams, , M. McMahon

This paper identifies RBMS3 as a tumor suppressor that cooperates with BRAFV600E to promote malignant lung cancer progression using transposon mutagenesis and CRISPR validation.

bioRxiv · Feb 28, 2022 · PreprintCancer Biology